Pharmaceutical / Drug Definition :
Interferes with prostaglandin biosynthesis by inhibiting cyclooxygenase pathway of arachidonic acid metabolism; also acts as potent inhibitor of platelet aggregation
FDA Label Requirements and Exceptions
Ketorolac Tromethamine
FDA Import Information
Ketorolac Tromethamine
FDA Detentions
Ketorolac Tromethamine (Ketorolac Tromethamine Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Ketorolac Tromethamine (Ketorolac Tromethamine Suppliers)
- Processors Ketorolac Tromethamine
- Repackers Ketorolac Tromethamine
- Relabelers Ketorolac Tromethamine
- Exporters Ketorolac Tromethamine
- Importers Ketorolac Tromethamine
For more information about Ketorolac Tromethamine, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
